Showing 1,381 - 1,400 results of 2,897 for search '"Stem cell"', query time: 0.10s Refine Results
  1. 1381
  2. 1382
  3. 1383

    Increased Co-Expression of PD-L1 and CTLA-4 Predicts Poor Overall Survival in Patients with Acute Myeloid Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation by Chen C, Qiu K, Chen J, Wang S, Zhang Y, Wang C, Li Y

    Published 2025-01-01
    “…This study aims to investigate the significance of the alteration of IC co-expression for evaluating the prognosis of AML patients following allogeneic hematopoietic stem cell transplantation (allo-HSCT).Patients and Methods: Quantitative real-time PCR (qRT-PCR) data of bone marrow (BM) samples from 62 de novo AML patients, including 37 patients who received allo-HSCT and 25 patients who received chemotherapy only, were used for prognostic analysis.Results: High expression of PD-1, PD-L1, PD-L2, CTLA-4, and LAG-3 was associated with poor overall survival (OS) in AML patients receiving allo-HSCT, while the expression levels of PD-1, PD-L2, CTLA-4, and LAG-3, other than PD-L1, were not significantly correlated with OS in AML patients receiving chemotherapy. …”
    Get full text
    Article
  4. 1384
  5. 1385
  6. 1386

    Exosomal miR-122 derived from M2 macrophages induces osteogenic differentiation of bone marrow mesenchymal stem cells in the treatment of alcoholic osteonecrosis of the femoral head by Guoping Le, Riyou Wen, Huaixi Fang, Zhifa Huang, Yong Wang, Hanwen Luo

    Published 2025-01-01
    “…M2-macrophage-derived exosomal miR-122 induces osteogenic differentiation of bone mesenchymal stem cells in treating AIONFH.…”
    Get full text
    Article
  7. 1387
  8. 1388

    The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies During Haploidentical Hematopoietic Stem Cell Transplantation by Xiaoping Li, Yu Li, Dingsong Zhang, Xiaozhuang Hu, Lin Liu, Zhongtao Yuan, Shiqi Li, Yancheng Dong, Yingnian Chen, Sanbin Wang

    Published 2025-01-01
    “…Donor-specific antibodies (DSAs) are essential causes of graft rejection in haploidentical hematopoietic stem cell transplantation (haplo-HSCT). DSAs are unavoidable for some patients who have no alternative donor. …”
    Get full text
    Article
  9. 1389
  10. 1390
  11. 1391
  12. 1392

    A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies by Melhem M. Solh, Gabriel Hinojosa, Justin Laporte, Scott R. Solomon, Lawrence E. Morris, Xu Zhang, H. Kent Holland, Asad Bashey

    Published 2021-01-01
    “…We have also developed myeloablative conditioning and peripheral blood stem cell (PBSC) grafts for use with haplo. However, some patients may not tolerate myeloablative conditioning but may still benefit from a more dose-intensified preparative regimen to control malignancy and diminish graft rejection. …”
    Get full text
    Article
  13. 1393
  14. 1394
  15. 1395
  16. 1396
  17. 1397
  18. 1398
  19. 1399

    Effects of Combined Intrathecal Mesenchymal Stem Cells and Schwann Cells Transplantation on Neuropathic Pain in Complete Spinal Cord Injury: A Phase II Randomized Active-Controlled Trial by Mohammadhosein Akhlaghpasand, Roozbeh Tavanaei, Maede Hosseinpoor, Reza Heidari, Ida Mohammadi, Mohsen Chamanara, Melika Hosseinpour, Alireza Zali, Reza Mosaed, Saeed Oraee-Yazdani

    Published 2025-01-01
    “…This clinical trial aimed to investigate the efficacy of combined intrathecal injection of Schwann cells (SCs) and bone marrow–derived mesenchymal stem cells (BMSCs) in improving SCI-induced neuropathic pain. …”
    Get full text
    Article
  20. 1400